<DOC>
	<DOC>NCT01294787</DOC>
	<brief_summary>This study assessed the effect of once-daily indacaterol and glycopyrronium bromide (QVA149) on exercise endurance in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).</brief_summary>
	<brief_title>Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Diagnosis of moderate to severe stable Chronic Obstructive Pulmonary Disease (COPD) stage II or stage III according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines (2009) Qualifying spirometry, Forced Expiratory Volume in one second (FEV1) and postbronchodilator FEV1/FVC (Forced Vital capacity) Smoking history â‰¥ 10 pack years Pregnant women or nursing mothers or women of childbearing potential not using adequate contraception Cardiac abnormality History of asthma Contraindications to cardiopulmonary exercise testing Participation in active phase of pulmonary rehabilitation program History of cancer within the past 5 years Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>COPD</keyword>
	<keyword>QVA149</keyword>
	<keyword>tiotropium</keyword>
	<keyword>exercise</keyword>
	<keyword>exercise tolerance</keyword>
	<keyword>combination bronchodilator</keyword>
	<keyword>moderate to severe COPD</keyword>
</DOC>